发明名称 CANNABINOID RECEPTOR LIGAND
摘要 <P>PROBLEM TO BE SOLVED: To treat inflammation and diseases characterized by immunomodulatory irregularities. Ž<P>SOLUTION: There are disclosed the compounds of the following formula, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of the prodrug, which exhibit anti-inflammatory and immunomodulatory activity. Also there are disclosed pharmaceutical compositions containing the compounds and methods of using the compounds for the treatment of various diseases and conditions. The invention relates to a cannabinoid receptor ligand, in particular, to a compound binding to the cannabinoid (CB<SB>2</SB>) receptor ligand. The compound generally exhibits anti-inflammatory and immunomodulatory activity, and is useful in treating inflammation and diseases characterized by immunomodulatory irregularities. Ž<P>COPYRIGHT: (C)2010,JPO&INPIT Ž
申请公布号 JP2010024251(A) 申请公布日期 2010.02.04
申请号 JP20090253551 申请日期 2009.11.04
申请人 SCHERING CORP 发明人 KOZLOWSKI JOSEPH A;SHIH NENG-YANG;LAVEY BRIAN J;RIZVI RAZIA K;SHANKAR BANDARPALLE B;SPITLER JAMES M;TONG LING;WOLIN RONALD;WONG MICHAEL K
分类号 C07C217/58;C07D295/08;A61K31/12;A61K31/137;A61K31/165;A61K31/17;A61K31/18;A61K31/192;A61K31/235;A61K31/277;A61K31/381;A61K31/4164;A61K31/44;A61K31/4402;A61K31/495;A61K31/519;A61K31/5375;A61K31/573;A61K31/635;A61K38/00;A61K45/00;A61P1/04;A61P1/16;A61P3/10;A61P5/14;A61P9/00;A61P9/10;A61P11/00;A61P11/02;A61P11/06;A61P11/08;A61P13/12;A61P17/00;A61P17/06;A61P19/02;A61P19/10;A61P21/04;A61P25/00;A61P27/02;A61P27/06;A61P27/16;A61P29/00;A61P31/04;A61P35/00;A61P35/02;A61P37/02;A61P37/06;A61P37/08;A61P43/00;C07C31/24;C07C233/18;C07C317/22;C07C317/24;C07C317/32;C07C317/36;C07C317/40;C07C317/42;C07C317/44;C07C321/30;C07C323/40;C07C323/41;C07C323/56;C07C323/65;C07D213/70;C07D213/71;C07D213/74;C07D213/89;C07D215/36;C07D233/42;C07D233/84;C07D239/38;C07D295/18;C07D295/20;C07D307/64;C07D333/20;C07D333/34;C07D333/38 主分类号 C07C217/58
代理机构 代理人
主权项
地址